©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2015; 21(3): 786-793
Published online Jan 21, 2015. doi: 10.3748/wjg.v21.i3.786
Published online Jan 21, 2015. doi: 10.3748/wjg.v21.i3.786
Role of E3 ubiquitin ligases in gastric cancer
Ya-Chao Hou, Jing-Yu Deng, Department of Gastroenterology, Cancer Hospital of Tianjin Medical University, City Key Laboratory of Tianjin Cancer Center, and National Clinical Research Center of Cancer, Tianjin 300060, China
Author contributions: Hou YC and Deng JY contributed equally to this work; Hou YC wrote the paper; and Deng JY designed the research.
Correspondence to: Jing-Yu Deng, MD, PhD, Department of Gastroenterology, Cancer Hospital of Tianjin Medical University, City Key Laboratory of Tianjin Cancer Center, and National Clinical Research Center of Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China. dengery@126.com
Telephone: +86-22-23340123 Fax: +86-22-23359904
Received: September 1, 2014
Peer-review started: September 7, 2014
First decision: October 14, 2014
Revised: November 1, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: January 21, 2015
Processing time: 136 Days and 22.6 Hours
Peer-review started: September 7, 2014
First decision: October 14, 2014
Revised: November 1, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: January 21, 2015
Processing time: 136 Days and 22.6 Hours
Core Tip
Core tip: E3 biquitin ligases are a large family of proteins that catalyze the ubiquitination of many protein substrates for targeted degradation by the 26S proteasome. They play an essential role in a variety of biological processes, including cell cycle regulation, proliferation and apoptosis. They are often found overexpressed in gastric cancer (GC) and their deregulation has been shown to contribute to GC development. The mechanisms of E3 ubiquitin ligases in the regulation of biological functions and their exact roles in carcinogenesis can help to develop specific E3 ubiquitin ligase inhibitors to improve the treatment strategies for GC patients.